Matrix metalloproteinase 13 (MMP13), a member of the MMP family, is a zinc-dependent endopeptidase involved in degrading extracellular matrix (ECM) components, particularly type II collagen. It plays critical roles in physiological processes like tissue remodeling, wound healing, and bone development, but its dysregulation is linked to pathological conditions such as osteoarthritis, cancer metastasis, and chronic inflammation. In osteoarthritis, MMP13 overexpression accelerates cartilage degradation by breaking down collagen networks, making it a key therapeutic target.
MMP13 antibodies are immunodetection tools designed to specifically recognize and bind to MMP13 proteins. These antibodies, often monoclonal or polyclonal, are widely used in research to study MMP13 expression patterns, localization, and activity in tissues or biofluids. Applications include immunohistochemistry, Western blotting, and ELISA. Some antibodies distinguish between latent (pro-MMP13) and active enzyme forms, aiding mechanistic studies. Additionally, therapeutic MMP13-neutralizing antibodies are under exploration to inhibit excessive collagenolysis in diseases like osteoarthritis, though challenges remain in balancing efficacy and off-target effects.
As a biomarker, MMP13 antibody-based assays help correlate enzyme levels with disease progression. Their development continues to advance understanding of MMP13's pathophysiological roles and potential intervention strategies.